골관절염 주사제 시장 규모, 점유율, 동향 분석 보고서 : 주사제 유형별, 해부학적 부위별, 최종 용도별 및 부문별 예측(2026-2033년)

Osteoarthritis Injectable Market Summary

The global osteoarthritis injectable market size was valued at USD 8.18 billion in 2025 and is projected to reach USD 14.16 billion by 2033, growing at a CAGR of 7.17% from 2026 to 2033. This growth is primarily driven by the increasing prevalence of osteoarthritis (OA), particularly among the aging population, as well as rising awareness of minimally invasive treatment options.

Additionally, advancements in biologic therapies and next-generation injectable, along with supportive reimbursement policies in key regions, are expected to further propel market expansion over the forecast period. R&D activities in injectable osteoarthritis therapies are accelerating due to challenges in delivering drugs into dense joint tissues. Companies are focusing on intra-articular biologics and disease-modifying agents. Candidates like lorecivivint from Biosplice Therapeutics and TPX-100 from OrthoTrophix highlight ongoing innovation. For instance, in January 2026, Biosplice Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA for lorecivivint, an intra-articular injection for knee osteoarthritis, which showed promising Phase III results for pain reduction and functional improvement.

Similarly, in March 2026, OrthoTrophix advanced its Phase 2b clinical trial of TPX-100 by completing patient enrollment, reinforcing its position in developing disease-modifying intra-articular therapies targeting cartilage regeneration in osteoarthritis. The growing emphasis on personalized medicine is reshaping the OA injectable market, with a greater focus on patient-specific biologics and regenerative therapies. Research from Columbia University on cartilage-regenerating stem cells highlights the potential for precision-based injectable treatments targeting early-stage disease progression.

Global Osteoarthritis Injectable Market Repoprt Segmentation

This report forecasts revenue growth at, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global osteoarthritis injectable market report on the basis of injection type, anatomy, end use, and region:

• Injection Type Outlook (Revenue, USD Million, 2021 - 2033)
• Hyaluronic Acid Injections
• Corticosteroid Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Acetylsalicylic Acid (ASA) Injections
• Others
• Anatomy Outlook (Revenue, USD Million, 2021 - 2033)
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Injection Type
  • 1.2.2. Anatomy
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Injection Type
  • 2.2.2. End Use
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Global Osteoarthritis Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of osteoarthritis
    • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
    • 3.2.1.3. Increase in R&D activities for injectable drug development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adoption of other treatment options
    • 3.2.2.2. High cost of treatment
• 3.3. Global Osteoarthritis Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social Landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal Landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Global Osteoarthritis Injectable Market: Injection Type Estimates & Trend Analysis

• 4.1. Injection Type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Osteoarthritis Injectable Market by Injection Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Hyaluronic Acid Injections
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.2. Corticosteroid Injections
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.3. Platelet-rich Plasma (PRP) Injections
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.4. Placental Tissue Matrix (PTM) Injections
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.5. Acetylsalicylic Acid (ASA) Injections
    • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.6. Others
    • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Global Osteoarthritis Injectable Market: Anatomy Estimates & Trend Analysis

• 5.1. Anatomy Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Osteoarthritis Injectable Market by Anatomy Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Knee Osteoarthritis
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.4.2. Hip Osteoarthritis
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.4.3. Hand Osteoarthritis
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 5.4.4. Others
    • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Global Osteoarthritis Injectable Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Osteoarthritis Injectable Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Hospital Pharmacies
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.4.2. Retail Pharmacies
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.4.3. Others
    • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Global Osteoarthritis Injectable Market: Regional Estimates & Trend Analysis by

• 7.1. Regional Market Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Anika Therapeutics, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Injection Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bioventus.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Injection Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Ferring Pharmaceuticals Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Injection Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sanofi S.A.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Injection Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Flexion Therapeutics, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Injection Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Zimmer Biomet
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Injection Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Arthrex, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Injection Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Royal Biologics
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Injection Type benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Teva Pharmaceutical Industries Ltd.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Injection Type benchmarking
    • 8.3.12.4. Strategic initiatives

Chapter 9. Conclusion and Analyst Perspective